Currently, out of the existing stock ratings of Leah Cann - 2708 which are a Buy (98.76%), 34 which are a Hold (1.24%)

Leah Cann

Work Performance Price Targets & Ratings Chart

Analyst Leah Cann works at BROOKLINE and is covering the Healthcare sector with 130 price targets and ratings displayed on 14 stocks. Previously, Leah Cann worked at OPPENHEIMER.

Leah Cann's average stock forecast success ratio is 41.67% with an average time for price targets to be met of 191.5 days.

Most recent stock forecast was given on MRNA, Moderna at 22-Jun-2022.

Wall Street Analyst Leah Cann

Analyst best performing recommendations are on SYRS.
The best stock recommendation documented was for MRNA (MODERNA) at 11/25/2020. The price target of $164 was fulfilled within 13 days with a profit of $54.82 (50.21%) receiving and performance score of 38.62.

Average potential price target upside

of $44.49 (30.37%) on AMGN (AMGEN).
of $31.73 (31.06%) on MRNA (MODERNA).
of $9.7 (30.04%) on MRTX (MIRATI THERAPEUTICS).

AMGN Amgen CELG CTIC CTI BioPharma MEIP MEI Pharma MRNA Moderna SQZ SQZ Biotechnologies Company CCCC C4 Therapeutics CRBU KURA Kura Oncology SYRS MRTX Mirati Therapeutics NTLA Intellia Therapeutics VSTM Verastem XFOR

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Robyn Karnauskas (TRUIST)